EQS-News: Sartorius sharpens climate targets and receives validation from Science Based Targets initiative
|
EQS-News: SARTORIUS AG
/ Key word(s): Sustainability/ESG
Göttingen, Germany | February 16, 2026
Sartorius sharpens climate targets and receives validation from Science Based Targets initiative
The life science group Sartorius has sharpened its medium-term climate targets and received validation from the Science Based Targets initiative (SBTi). The organization confirmed that the new greenhouse gas reduction targets are in line with the Paris Climate Agreement. “We have refined our climate targets and, with SBTi validation, taken an important step that is increasingly expected in our industry: science-based targets aligned with the United Nations’ decarbonization pathways. This underscores our level of ambition,” said Sartorius CEO Dr. Michael Grosse. “At the same time, we are turning ambition into action: We are transitioning our sites to renewable energy, working closely with customers and suppliers to advance the use of low-emission materials and processes, and applying eco-design principles to a growing share of our product portfolio. This is how we reduce our own footprint and help our customers achieve their sustainability goals.” For direct emissions from its own operations and vehicle fleet, as well as indirect emissions from purchased energy - Scopes 1 and 2 -, Sartorius aims to reduce CO₂ equivalents in metric tons by 42 percent by 2030 compared with the base year 2022. The target now covers all relevant emission sources and exceeds the 95 percent coverage required by the Science Based Targets initiative. According to SBTi criteria, it is therefore aligned with the United Nations’ 1.5-degree Celsius target. The most important lever for reducing Scope 1 and 2 emissions at Sartorius remains the global transition of sites to renewable energy. An increasing number of facilities are to source electricity from renewable sources and heat, cooling, and steam is also planned to be generated sustainably. For indirect emissions along the company’s value chain, the Sartorius Executive Board has defined an intensity target, assuming continued business growth: The company plans to reduce its Scope 3 emissions by 51.6 percent by 2030 compared to 2022 relative to the company’s value added1. The most important drivers are the decarbonization of the supply chain together with customers and suppliers, the eco-design of products and packaging, logistics, and sustainable building construction. The company’s long-term climate ambition remains unchanged: Sartorius aims to have a climate-neutral value chain by 2045 and achieve net-zero greenhouse gas emissions by eliminating all avoidable emissions and offsetting the remaining ones. The updated climate targets remain part of the long-term remuneration components of the Executive Board and replace the previous ones. Learn more: www.sartorius.com/sustainability A profile of Sartorius Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Göttingen-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees serve customers around the globe. Visit our newsroom and follow us on LinkedIn. Contact Leona Malorny Head of External Communications +49 551 308 4067 leona.malorny@sartorius.com Additional features: File: 20260216_SAG_Media Release_Sartorius sharpens climate targets_en File: Photo_Sartorius Campus in Göttingen
16.02.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | SARTORIUS AG |
| Otto-Brenner-Straße 20 | |
| 37079 Göttingen | |
| Germany | |
| Phone: | +49.(0)551-308.0 |
| Fax: | +49.(0)551-308.3289 |
| E-mail: | info@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | DE0007165631, DE0007165607 |
| WKN: | 716563, 716560 |
| Indices: | MDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX |
| EQS News ID: | 2276308 |
| End of News | EQS News Service |
|
|
2276308 16.02.2026 CET/CEST
Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL.
| Die wichtigsten Finanzdaten auf einen Blick | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | ||
| Umsatzerlöse1 | 2.335,66 | 3.449,22 | 4.174,70 | 3.395,70 | 3.380,70 | 3.538,10 | 3.805,00 | |
| EBITDA1,2 | 636,70 | 1.134,26 | 1.410,40 | 962,70 | 945,30 | 1.051,60 | 1.165,00 | |
| EBITDA-Marge3 | 27,26 | 32,89 | 33,78 | 28,35 | 27,96 | 29,72 | 30,62 | |
| EBIT1,4 | 456,11 | 903,16 | 1.064,80 | 503,90 | 530,00 | 542,60 | 565,00 | |
| EBIT-Marge5 | 19,53 | 26,18 | 25,51 | 14,84 | 15,68 | 15,34 | 14,85 | |
| Jahresüberschuss1 | 299,56 | 426,98 | 913,10 | 290,60 | 137,40 | 230,40 | 250,00 | |
| Netto-Marge6 | 12,83 | 12,38 | 21,87 | 8,56 | 4,06 | 6,51 | 6,57 | |
| Cashflow1,7 | 511,53 | 865,81 | 734,20 | 853,60 | 976,00 | 837,00 | 860,00 | |
| Ergebnis je Aktie8 | 4,38 | 8,09 | 9,58 | 4,95 | 5,30 | 4,79 | 5,30 | |
| Dividende8 | 0,71 | 1,26 | 1,44 | 0,74 | 0,74 | 0,74 | 1,44 | |
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: PricewaterhouseCoopers
Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.
| INVESTOR-INFORMATIONEN | ||||||
| ©boersengefluester.de | ||||||
| Sartorius VZ | ||||||
| WKN | ISIN | Rechtsform | Börsenwert | IPO | Einschätzung | Plus Code |
| 716563 | DE0007165631 | AG | 15.095,81 Mio € | 10.07.1990 | Halten | 9F3FHV2Q+JW |
| KGV 2027e | KGV 10Y-Ø | BGFL-Ratio | Shiller-KGV | KBV | KCV | KUV |
| 37,60 | 40,40 | 0,93 | 51,87 | 6,36 | 20,18 | 4,27 |
|
Dividende '2023 in € |
Dividende '2024 in € |
Dividende '2025e in € |
Div.-Rendite '2025e in % |
| 0,74 | 0,74 | 0,74 | 0,34% |
| Hauptversammlung | Q1-Zahlen | Q2-Zahlen | Q3-Zahlen | Bilanz-PK |
| 26.03.2026 | 23.04.2026 | 23.07.2026 | 22.10.2026 | 16.02.2026 |
| Abstand 60-Tage-Linie | Abstand 200-Tage-Linie | Performance YtD | Kursveränderung 52 Wochen | IPO |
| -6,12% | +1,67% | -10,88% | -10,01% | +3.656,18% |
Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.